Fig 6. DC and CD4⁺ T cell accumulation and their C5aR1 expression in mLN of WT and GFP-C5aR1^flox/flox mice in the allergic effector phase.

(A) Cell counts of cDC and moDC subsets in mLN of WT or GFP-C5aR1^flox/flox mice in response to PBS treatment or OVA immunization; n = 7–15 per group. CD11b⁺ cDC data were analyzed by ANOVA on ranks (n = 7–15). (B) Counts of different CD4⁺ T cell subsets in mLN of PBS-treated or OVA-challenged WT or GFP-C5aR1^flox/flox animals. Values shown are the mean ± SEM; n = 7–15 per group. * indicates significant differences between PBS and OVA treatment groups; § indicates significant differences between WT and GFP-C5aR1^flox/flox OVA-treated groups. * or § p < 0.05; ** p < 0.001. (C) GFP signal in CD4⁺ or CD4⁺CD44⁺CD62L^- effector T cells from OVA-challenged WT (grey histogram) or GFP-C5aR1^flox/flox animals (black line).